Semaglutide (GLP-1 RA) significantly reduced the incidence of primary endpoint expanded composite outcome [CV death, nonfatal MI, nonfatal stroke, revascularization (coronary or peripheral), Patients treated with semaglutide had a lower risk of developing or worsening nephropathy, but a higher risk of complications from diabetic retinopathy than those receiving placebo. This evidence concerns the gene GLP1R and kidney disorder.